Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...

David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, ...

Panelists discuss how the decision to initiate cytoreductive therapy in polycythemia vera (PV) is driven by high-risk ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell ...

Jyoti Srivastava, PhD, discusses a study investigating methods to boost inhibitor function in advanced melanoma.

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in transplant-ineligible, newly diagnosed multiple myeloma.

A panelist discusses how successful management of chronic graft-vs-host disease (cGVHD) requires a multifaceted approach that combines prompt recognition, strategic intervention, and comprehensive ...

Panelists discuss how frequent phlebotomy requirements—typically more than 4 to 6 times per year—serve as a marker of inadequate disease control in polycythemia vera (PV), prompting consideration of ...

Check out the latest oncology news from this week, including highlights from the 2025 American Association for Cancer Research and American Urological Association annual meetings.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...